Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

ODAC to discuss Daiichi Sankyo's pexidartinib, quizartinib NDAs

Meghan Sullivan, Assistant Editor
April 12, 2019 6:59 PM UTC

FDA’s Oncologic Drugs Advisory Committee will meet on May 14 to discuss two NDAs from Daiichi Sankyo, one for pexidartinib to treat symptomatic tenosynovial giant cell tumors and the other for quizartinib to treat relapsed or refractory FLT3-internal tandem duplication (ITD) mutation-positive acute myelogenous leukemia (AML).

Pexidartinib is a small molecule inhibitor of CSF1R, c-Kit and FLT3. Quizartinib is a small molecule FLT3 inhibitor...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Daiichi Sankyo Co. Ltd.